National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

IGF-1R antagonist BMS-754807
An orally bioavailable antagonist of human insulin-like growth factor type I receptor (IGF-1R) with potential antineoplastic activity. IGF-1R antagonist BMS-7548077 binds to IGF-1R, preventing IGF-1 ligand binding and activation of IGF-1R-mediated signaling pathways; inhibition of IGF-1R-mediated signaling pathways may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. IGF-1R is a receptor tyrosine kinase expressed on most tumor cells and is involved in mitogenesis, angiogenesis, and tumor cell survival. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Code name:BMS-754807



Previous:idiotype-pulsed autologous dendritic cell vaccine APC8020, idoxuridine, Ifex, ifosfamide, Ifosfamidum
Next:IGF-1R inhibitor OSI-906, IH636 grape seed proanthocyanidin extract, IL-2 plasmid DNA/lipid complex, IL-2 recombinant fusion protein ALT-801, IL-2/Lptn gene-modified allogeneic neuroblastoma tumor cell vaccine

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov